FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer](https://www.europesays.com/ch/wp-content/uploads/2026/03/964824-380x220.png)
